Chad Robins's most recent trade in Adaptive Biotechnologies Corp was a trade of 709,220 Common Stock done . Disclosure was reported to the exchange on March 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 709,220 | 2,771,280 (2%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2026 | 127,813 | 2,062,060 (1%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 15.82 per share. | 27 Feb 2026 | 289,024 | 1,987,330 (1%) | 0% | 15.8 | 4,572,360 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 15.99 per share. | 27 Feb 2026 | 182,891 | 2,276,354 (1%) | 0% | 16.0 | 2,924,427 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 15.49 per share. | 27 Feb 2026 | 50,703 | 1,936,627 (1%) | 0% | 15.5 | 785,389 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 16.15 per share. | 27 Feb 2026 | 2,380 | 1,934,247 (1%) | 0% | 16.2 | 38,437 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 18.44 per share. | 02 Feb 2026 | 124,998 | 2,459,245 (1%) | 0% | 18.4 | 2,304,963 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 15.59 per share. | 05 Jan 2026 | 124,998 | 2,584,243 (2%) | 0% | 15.6 | 1,948,719 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 18.94 per share. | 26 Nov 2025 | 124,998 | 2,709,241 (2%) | 0% | 18.9 | 2,367,462 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 19.68 per share. | 26 Nov 2025 | 35,736 | 2,834,239 (2%) | 0% | 19.7 | 703,284 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 14.73 per share. | 10 Nov 2025 | 86,161 | 2,873,088 (2%) | 0% | 14.7 | 1,269,152 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 10 Nov 2025 | 1,867 | 2,869,975 (2%) | 0% | 15 | 28,005 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 14.57 per share. | 10 Nov 2025 | 1,237 | 2,871,851 (2%) | 0% | 14.6 | 18,023 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 355,000 | 2,931,701 (2%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 247,117 | 3,061,467 (2%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 7.64 per share. | 04 Mar 2025 | 102,218 | 2,959,249 (2%) | 0% | 7.6 | 780,946 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 6.98 per share. | 04 Mar 2025 | 81,206 | 2,850,495 (2%) | 0% | 7.0 | 566,818 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 04 Mar 2025 | 36,145 | 2,814,350 (2%) | 0% | 7.0 | 252,654 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Feb 2025 | 186,080 | 2,762,781 (2%) | 0% | 6.3 | 1,176,026 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.46 per share. | 19 Feb 2025 | 186,080 | 2,576,701 (2%) | 0% | 8.5 | 1,574,237 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 186,080 | 99,107 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 19 Feb 2025 | 99,107 | 2,675,808 (2%) | 0% | 6.3 | 626,356 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.44 per share. | 19 Feb 2025 | 99,107 | 2,576,701 (2%) | 0% | 8.4 | 836,463 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2025 | 99,107 | 0 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 211,160 | 2,787,861 (2%) | 0% | 6.3 | 1,334,531 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.50 per share. | 13 Feb 2025 | 211,160 | 2,576,701 (2%) | 0% | 8.5 | 1,794,860 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 211,160 | 285,187 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 158,921 | 2,735,622 (2%) | 0% | 6.3 | 1,004,381 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.46 per share. | 13 Feb 2025 | 158,921 | 2,576,701 (2%) | 0% | 8.5 | 1,344,472 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 158,921 | 496,347 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 13 Feb 2025 | 100,287 | 2,676,988 (2%) | 0% | 6.3 | 633,814 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 8.44 per share. | 13 Feb 2025 | 100,287 | 2,576,701 (2%) | 0% | 8.4 | 846,422 | Common Stock |
| Adaptive biotech Corp | Chad M. Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 100,287 | 655,268 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 354,610 | 2,625,374 (2%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 3.43 per share. | 04 Mar 2024 | 42,794 | 2,576,701 (2%) | 0% | 3.4 | 146,783 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 3.44 per share. | 04 Mar 2024 | 5,879 | 2,619,495 (2%) | 0% | 3.4 | 20,224 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 354,610 | 2,270,764 (1%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 07 Mar 2022 | 14,815 | 1,930,969 (1%) | 0% | 6.3 | 93,631 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 11.38 per share. | 07 Mar 2022 | 14,815 | 1,916,154 (1%) | 0% | 11.4 | 168,595 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 07 Mar 2022 | 14,815 | 1,930,969 (1%) | 0% | 6.3 | 93,631 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 14,815 | 755,555 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 14,815 | 770,370 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2022 | 14,815 | 785,185 | - | - | Stock Option (Right to Buy) | |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 12.46 per share. | 07 Mar 2022 | 14,815 | 1,916,154 (1%) | 0% | 12.5 | 184,595 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.32 per share. | 07 Mar 2022 | 14,815 | 1,930,969 (1%) | 0% | 6.3 | 93,631 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 11.53 per share. | 07 Mar 2022 | 14,315 | 1,916,154 (1%) | 0% | 11.5 | 165,052 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 12.22 per share. | 07 Mar 2022 | 500 | 1,930,469 (1%) | 0% | 12.2 | 6,110 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 247,117 | 1,920,578 (1%) | 0% | 0 | Common Stock | |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 04 Mar 2022 | 4,424 | 1,916,154 (1%) | 0% | 12.0 | 53,132 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.24 per share. | 12 Jul 2021 | 1,501 | 1,716,960 (1%) | 0% | 38.2 | 57,398 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.22 per share. | 15 Jun 2021 | 19,100 | 1,729,361 (1%) | 0% | 38.2 | 730,002 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.13 per share. | 15 Jun 2021 | 4,745 | 1,723,716 (1%) | 0% | 38.1 | 180,927 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 39.76 per share. | 15 Jun 2021 | 4,255 | 1,718,461 (1%) | 0% | 39.8 | 169,179 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 38.55 per share. | 15 Jun 2021 | 1,000 | 1,722,716 (1%) | 0% | 38.6 | 38,550 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 39.23 per share. | 15 Jun 2021 | 900 | 1,728,461 (1%) | 0% | 39.2 | 35,307 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 40.61 per share. | 06 Apr 2021 | 3,900 | 1,754,561 (1%) | 0% | 40.6 | 158,379 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.04 per share. | 06 Apr 2021 | 2,943 | 1,750,518 (1%) | 0% | 42.0 | 123,724 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.48 per share. | 06 Apr 2021 | 2,200 | 1,759,661 (1%) | 0% | 42.5 | 93,456 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.00 per share. | 06 Apr 2021 | 1,957 | 1,748,561 (1%) | 0% | 43 | 84,151 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.08 per share. | 06 Apr 2021 | 1,600 | 1,761,861 (1%) | 0% | 41.1 | 65,728 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.08 per share. | 06 Apr 2021 | 1,200 | 1,758,461 (1%) | 0% | 43.1 | 51,696 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.45 per share. | 06 Apr 2021 | 1,100 | 1,753,461 (1%) | 0% | 41.5 | 45,595 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.78 per share. | 06 Apr 2021 | 100 | 1,748,461 (1%) | 0% | 43.8 | 4,378 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.96 per share. | 17 Mar 2021 | 4,900 | 1,763,561 (1%) | 0% | 42.0 | 205,604 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.81 per share. | 17 Mar 2021 | 2,604 | 1,768,931 (1%) | 0% | 42.8 | 111,477 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 41.90 per share. | 17 Mar 2021 | 1,926 | 1,771,535 (1%) | 0% | 41.9 | 80,699 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.22 per share. | 17 Mar 2021 | 1,901 | 1,776,560 (1%) | 0% | 43.2 | 82,161 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 45.25 per share. | 17 Mar 2021 | 1,804 | 1,773,461 (1%) | 0% | 45.3 | 81,631 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 44.03 per share. | 17 Mar 2021 | 1,295 | 1,775,265 (1%) | 0% | 44.0 | 57,019 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 43.78 per share. | 17 Mar 2021 | 470 | 1,768,461 (1%) | 0% | 43.8 | 20,577 | Common Stock |
| Adaptive biotech Corp | Chad Robins | Director, CEO and Chairman | Sale of securities on an exchange or to another person at price $ 42.48 per share. | 17 Mar 2021 | 100 | 1,763,461 (1%) | 0% | 42.5 | 4,248 | Common Stock |